Fig. 2: GGCX promoted the infection of EA H1N1 SIV in vivo.

a Schematic of siRNA treatment and HuN/H1N1 strain challenge in an experimental mouse model. Mice were treated with siRNA the day before and after the viral challenge, and monitored for 14 days. b Western blot analysis of GGCX protein expression in GGCX-siRNA treated mice. c Weight loss of HuN/H1N1 strain infected mice after siRNA treatments. Mice with a body weight loss of more than 30% were euthanized according to the ethical principles of animal welfare. Each treatment group had ten mice (n  =  10) per group. d Mortality of HuN/H1N1 strain-infected mice after siRNA treatments. Each treatment group had ten mice (n  =  10) per group. e Virus titers in the lungs of infected mice 3 days (left) and 5 days (right) after infection. Each treatment group had three mice (n  =  3) per group. f Hematoxylin and eosin (H&E) staining of pathological lesions in the lungs of GGCX knockdown mice infected with HuN/H1N1 strain at 3 and 5 days post-challenge. Scale bars, 200 μm. g Immunofluorescence staining of lung sections from GGCX knockdown mice infected with HuN/H1N1 strain at 3 and 5 days post-challenge. The viral NP antigen was stained red, and the nucleus was stained blue. Scale bars, 200 μm. The images in panels (f and g) are representative of three independent experiments. The error bar in panels (c and e) indicates the standard deviation. The data shown in panels c and e are means ± SD (n = 10 for c and n  =  3 for e biologically independent experiments). Statistical analysis was performed using an unpaired, two-tailed Student’s t test. (**P < 0.01; ***P < 0.001). Exact P-values are available in the Source Data. Source data are provided as a Source Data file.